Effect of Nigella sativa oil extracts on inflammatory and oxidative stress markers in Behcet's disease: A randomized, double-blind, placebo-controlled clinical trial

被引:0
|
作者
Amizadeh, Shahrzad [1 ]
Rashtchizadeh, Nadereh [1 ]
Khabbazi, Alireza [1 ]
Ghorbanihaghjo, Amir [2 ]
Ebrahimi, Ali-Asghar [1 ]
Vatankhah, Amir-Mansour [3 ]
Mahdavi, Aida Malek [1 ]
Taghizadeh, Mohsen [4 ,5 ]
机构
[1] Tabriz Univ Med Sci, Connect Tissue Dis Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[4] Kashan Univ Med Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran
[5] Barij Essence Med Plants Res Ctr, Kashan, Iran
关键词
Nigella sativa; Behcet's disease; IL-10; TNF-alpha; Oxidative stress; RHEUMATOID-ARTHRITIS; CYTOKINE RESPONSE; THYMOQUINONE; PLASMA; LEUKOCYTES; SYNTHASE;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: Behcet's disease (BD) is a chronic inflammatory disorder characterized by recurrent oral and genital aphthous ulcers, uveitis and skin lesions. Oxidative stress and inflammation have important role in the pathogenesis of BD. The aim of this study was to assess the effect of Nigella sativa (NS) oil administration on malondialdehyde (MDA), total anti-oxidant capacity (TAC), tumor necrosis factor-alpha (TNF-alpha), IL-10 and high sensitivity C-reactive protein (hs- CRP) levels in patients with BD. Materials and Methods: In this randomized, double-blind and placebo-controlled clinical trial, 96 BD patients were randomly assigned to NS or placebo groups. Study groups received 1000 mg/day NS oil and placebo soft gels for 8 weeks. Serum levels of TNF-alpha, IL-10, hs-CRP, MDA and TAC were measured before and after treatment. Results: Eighty-nine individuals completed the study. Significant decreases in the serum levels of MDA and increases in the serum levels of TAC were found in the NS group. However, differences in the changes of MDA and TAC in the NS and placebo groups were not significant. Pre- and post-intervention changes of TNF-alpha, IL-10 and hs-CRP levels in the NS group were non-significant. Conclusion: NS 1000 mg per day is probably not effective in reducing the inflammatory and oxidative markers in BD.
引用
收藏
页码:181 / 189
页数:9
相关论文
共 50 条
  • [41] Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly hypogonadal men: A double-blind placebo-controlled randomized trial
    Dougherty, R
    Rohrer, JL
    Hayden, D
    Leder, BZ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 182A - 182A
  • [42] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [43] The effects of synbiotic supplementation on oxidative stress markers, mental status, and quality of life in patients with Parkinson?s disease: A double-blind, placebo-controlled, randomized controlled trial
    Mehrabani, Sanaz
    Khorvash, Fariborz
    Heidari, Zahra
    Tajabadi-Ebrahimi, Maryam
    Amani, Reza
    JOURNAL OF FUNCTIONAL FOODS, 2023, 100
  • [44] Estrogen for Alzheimer's disease in women - Randomized, double-blind, placebo-controlled trial
    Henderson, VW
    Paganini-Hill, A
    Miller, BL
    Elble, RJ
    Reyes, PF
    Shoupe, D
    McCleary, CA
    Klein, RA
    Hake, AM
    Farlow, MR
    NEUROLOGY, 2000, 54 (02) : 295 - 301
  • [45] Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
    Martinuzzi, Andrea
    Liava, Alexandra
    Trevisi, Enrico
    Frare, Mara
    Tonon, Caterina
    Malucelli, Emil
    Manners, David
    Kemp, Graham J.
    Testa, Claudia
    Barbiroli, Bruno
    Lodi, Raffaele
    MUSCLE & NERVE, 2008, 37 (03) : 350 - 357
  • [46] Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
    Sandborn, WJ
    Hanauer, SB
    Katz, S
    Safdi, M
    Wolf, DG
    Baerg, RD
    Tremaine, WJ
    Johnson, T
    Diehl, NN
    Zinsmeister, AR
    GASTROENTEROLOGY, 2001, 121 (05) : 1088 - 1094
  • [47] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353
  • [48] A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson's disease
    Chong, K. K.
    Lim, S. Y.
    Manap, M. A. A. A.
    Lim, J. L.
    Low, S. C.
    Mahadeva, S. K.
    Tan, A. H.
    MOVEMENT DISORDERS, 2018, 33 : S194 - S194
  • [49] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [50] A randomized, double-blind, placebo-controlled trial of hydrogen water in Parkinson's disease
    Yoritaka, A.
    Takanashi, M.
    Hirayama, M.
    Ohta, S.
    Hattori, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 311 - 311